Keep up to date with stayble’s latest news and events

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company will participate in the investor meeting “Investera som proffsen,” organized by Financial Stockholm on September 25, 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc disease has been completed.  This means that the target number of evaluable patients in the study has now been reached twelve months after receiving treatment with STA363. The Phase 2b study, aimed at evaluating the pain relief of the drug candidate STA363, has been successfully concluded with high quality, good compliance and a low patient dropout rate. The company is following the previously communicated timeline and expects to communicate top line results in the fourth quarter of 2023.

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB (“Lago”). The agreement will cease to be effective on September 29, 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the first patient has been enrolled in the Company’s Phase 1b clinical study with STA363 for treatment of herniated discs. STA363 for Herniated discs is the second indication for the drug candidate STA363, which is also undergoing a clinical study in degenerative disc disease. Stayble has successfully completed a Phase 1b study in degenerative disc disease and is currently in the final phase of an ongoing Phase 2b study.